Phase II study of oxaliplatin in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines

Narikazu Boku, Atsushi Ohtsu, Ichinosuke Hyodo, Kuniaki Shirao, Yoshinori Miyata, Kazuhiko Nakagawa, Takao Tamura, Kiyohiko Hatake, Yusuke Tanigawara

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Although oxaliplatin (L-OHP) combined with infusional 5-fluorouracil (5-FU) and leucovorin (LV) is one of the standard chemotherapy regimens for metastatic or recurrent colorectal cancer, its introduction to Japan has been delayed. Phase I studies of L-OHP monotherapy in Japan showed no dose-limiting toxicity at the internationally recommended dose of 130 mg/m2 every 3 weeks, as well as no racial differences in pharmacokinetics as compared with Western subjects. This study aimed to clarify the efficacy and safety of L-OHP monotherapy in patients with metastatic colorectal cancer refractory to fluoropyrimidines. Methods: Patients with metastatic colorectal cancer who had failed to respond to fluoropyrimidine-based chemotherapy received L-OHP at a dose of 130 mg/m2 every 3 weeks. Results: Sixty patients were enrolled. Two ineligible patients and one untreated patient were excluded from analysis. The median number of treatment cycles was 4 (range, 1 - 6). The overall response rate was 9% (5/57, 95% CI: 4 - 19%). The median time to progression was 2.7 months, and the median survival time was 11.1 months. Grade 3 major toxicity comprised thrombocytopenia (12%) and nausea (11%). There was no grade 4 toxicity. All patients experienced mild to moderate sensory neurotoxicity without functional impairment interfering with activities of daily living. Conclusions: The efficacy and toxicity of L-OHP in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines is apparently similar to those in Western patients.

Original languageEnglish
Pages (from-to)440-445
Number of pages6
JournalJapanese Journal of Clinical Oncology
Volume37
Issue number6
DOIs
Publication statusPublished - 2007 Jun

Fingerprint

oxaliplatin
Colorectal Neoplasms
Japan
Drug Therapy
Leucovorin
Activities of Daily Living

Keywords

  • Colorectal cancer
  • Monotherapy
  • Oxaliplatin
  • Phase II

ASJC Scopus subject areas

  • Oncology

Cite this

Phase II study of oxaliplatin in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines. / Boku, Narikazu; Ohtsu, Atsushi; Hyodo, Ichinosuke; Shirao, Kuniaki; Miyata, Yoshinori; Nakagawa, Kazuhiko; Tamura, Takao; Hatake, Kiyohiko; Tanigawara, Yusuke.

In: Japanese Journal of Clinical Oncology, Vol. 37, No. 6, 06.2007, p. 440-445.

Research output: Contribution to journalArticle

Boku, Narikazu ; Ohtsu, Atsushi ; Hyodo, Ichinosuke ; Shirao, Kuniaki ; Miyata, Yoshinori ; Nakagawa, Kazuhiko ; Tamura, Takao ; Hatake, Kiyohiko ; Tanigawara, Yusuke. / Phase II study of oxaliplatin in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines. In: Japanese Journal of Clinical Oncology. 2007 ; Vol. 37, No. 6. pp. 440-445.
@article{e458ccffe2e241778c6aa6f7e89263dd,
title = "Phase II study of oxaliplatin in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines",
abstract = "Background: Although oxaliplatin (L-OHP) combined with infusional 5-fluorouracil (5-FU) and leucovorin (LV) is one of the standard chemotherapy regimens for metastatic or recurrent colorectal cancer, its introduction to Japan has been delayed. Phase I studies of L-OHP monotherapy in Japan showed no dose-limiting toxicity at the internationally recommended dose of 130 mg/m2 every 3 weeks, as well as no racial differences in pharmacokinetics as compared with Western subjects. This study aimed to clarify the efficacy and safety of L-OHP monotherapy in patients with metastatic colorectal cancer refractory to fluoropyrimidines. Methods: Patients with metastatic colorectal cancer who had failed to respond to fluoropyrimidine-based chemotherapy received L-OHP at a dose of 130 mg/m2 every 3 weeks. Results: Sixty patients were enrolled. Two ineligible patients and one untreated patient were excluded from analysis. The median number of treatment cycles was 4 (range, 1 - 6). The overall response rate was 9{\%} (5/57, 95{\%} CI: 4 - 19{\%}). The median time to progression was 2.7 months, and the median survival time was 11.1 months. Grade 3 major toxicity comprised thrombocytopenia (12{\%}) and nausea (11{\%}). There was no grade 4 toxicity. All patients experienced mild to moderate sensory neurotoxicity without functional impairment interfering with activities of daily living. Conclusions: The efficacy and toxicity of L-OHP in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines is apparently similar to those in Western patients.",
keywords = "Colorectal cancer, Monotherapy, Oxaliplatin, Phase II",
author = "Narikazu Boku and Atsushi Ohtsu and Ichinosuke Hyodo and Kuniaki Shirao and Yoshinori Miyata and Kazuhiko Nakagawa and Takao Tamura and Kiyohiko Hatake and Yusuke Tanigawara",
year = "2007",
month = "6",
doi = "10.1093/jjco/hym069",
language = "English",
volume = "37",
pages = "440--445",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "6",

}

TY - JOUR

T1 - Phase II study of oxaliplatin in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines

AU - Boku, Narikazu

AU - Ohtsu, Atsushi

AU - Hyodo, Ichinosuke

AU - Shirao, Kuniaki

AU - Miyata, Yoshinori

AU - Nakagawa, Kazuhiko

AU - Tamura, Takao

AU - Hatake, Kiyohiko

AU - Tanigawara, Yusuke

PY - 2007/6

Y1 - 2007/6

N2 - Background: Although oxaliplatin (L-OHP) combined with infusional 5-fluorouracil (5-FU) and leucovorin (LV) is one of the standard chemotherapy regimens for metastatic or recurrent colorectal cancer, its introduction to Japan has been delayed. Phase I studies of L-OHP monotherapy in Japan showed no dose-limiting toxicity at the internationally recommended dose of 130 mg/m2 every 3 weeks, as well as no racial differences in pharmacokinetics as compared with Western subjects. This study aimed to clarify the efficacy and safety of L-OHP monotherapy in patients with metastatic colorectal cancer refractory to fluoropyrimidines. Methods: Patients with metastatic colorectal cancer who had failed to respond to fluoropyrimidine-based chemotherapy received L-OHP at a dose of 130 mg/m2 every 3 weeks. Results: Sixty patients were enrolled. Two ineligible patients and one untreated patient were excluded from analysis. The median number of treatment cycles was 4 (range, 1 - 6). The overall response rate was 9% (5/57, 95% CI: 4 - 19%). The median time to progression was 2.7 months, and the median survival time was 11.1 months. Grade 3 major toxicity comprised thrombocytopenia (12%) and nausea (11%). There was no grade 4 toxicity. All patients experienced mild to moderate sensory neurotoxicity without functional impairment interfering with activities of daily living. Conclusions: The efficacy and toxicity of L-OHP in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines is apparently similar to those in Western patients.

AB - Background: Although oxaliplatin (L-OHP) combined with infusional 5-fluorouracil (5-FU) and leucovorin (LV) is one of the standard chemotherapy regimens for metastatic or recurrent colorectal cancer, its introduction to Japan has been delayed. Phase I studies of L-OHP monotherapy in Japan showed no dose-limiting toxicity at the internationally recommended dose of 130 mg/m2 every 3 weeks, as well as no racial differences in pharmacokinetics as compared with Western subjects. This study aimed to clarify the efficacy and safety of L-OHP monotherapy in patients with metastatic colorectal cancer refractory to fluoropyrimidines. Methods: Patients with metastatic colorectal cancer who had failed to respond to fluoropyrimidine-based chemotherapy received L-OHP at a dose of 130 mg/m2 every 3 weeks. Results: Sixty patients were enrolled. Two ineligible patients and one untreated patient were excluded from analysis. The median number of treatment cycles was 4 (range, 1 - 6). The overall response rate was 9% (5/57, 95% CI: 4 - 19%). The median time to progression was 2.7 months, and the median survival time was 11.1 months. Grade 3 major toxicity comprised thrombocytopenia (12%) and nausea (11%). There was no grade 4 toxicity. All patients experienced mild to moderate sensory neurotoxicity without functional impairment interfering with activities of daily living. Conclusions: The efficacy and toxicity of L-OHP in Japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines is apparently similar to those in Western patients.

KW - Colorectal cancer

KW - Monotherapy

KW - Oxaliplatin

KW - Phase II

UR - http://www.scopus.com/inward/record.url?scp=34547924451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547924451&partnerID=8YFLogxK

U2 - 10.1093/jjco/hym069

DO - 10.1093/jjco/hym069

M3 - Article

C2 - 17656482

AN - SCOPUS:34547924451

VL - 37

SP - 440

EP - 445

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 6

ER -